**Supplementary Table 1.** Dementia diagnoses from 2007 to 2013 in SveDem and ReDeGi stratified by age groups [n (%)].

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SveDem**  (n=22,384) | **ReDeGi** (n=5,032) | **Odds ratio**  (95% CI) |
| **Alzheimer's Disease** |  |  |  |
| <65 years | 740 (9.1) | 68 (2.4) | 4.01 (3.11-5.16) |
| 65-74 years | 2,190 (26.9) | 420 (15.0) | 2.08 (1.85-2.33) |
| 75+ years | 5,206 (64.0) | 2,308 (82.6) | 0.36 (0.32-0.40) |
| **Vascular dementia** |  |  |  |
| <65 years | 170 (4.0) | 32 (10.0) | 0.37 (0.25-0.56) |
| 65-74 years | 795 (18.9) | 67 (21.0) | 0.87 (0.66-1.15) |
| 75+ years | 3,242 (77.1) | 220 (69.0) | 1.51 (1.17-1.93) |
| **Mixed dementia** |  |  |  |
| <65 years | 87 (1.6) | 10 (1.5) | 1.04 (0.54-2.02) |
| 65-74 years | 845 (15.2) | 87 (13.0) | 1.19 (0.94-1.51) |
| 75+ years | 4,636 (83.3) | 573 (85.5) | 0.84 (0.67-1.05) |
| **Dementia with Lewy bodies** |  |  |  |
| <65 years | 33 (4.7) | 3 (1.2) | 3.98 (1.21-13.12) |
| 65-74 years | 202 (29.1) | 37 (15.3) | 2.28 (1.55-3.35) |
| 75+ years | 460 (66.2) | 203 (83.5) | 0.38 (0.26-0.56) |
| **Frontotemporal dementia** |  |  |  |
| <65 years | 154 (29.9) | 20 (13.6) | 2.70 (1.63-4.50) |
| 65-74 years | 185 (35.9) | 50 (34.0) | 1.08 (0.73-1.59) |
| 75+ years | 176 (34.2) | 77 (52.4) | 0.47 (0.32-0.68) |
| **Parkinson's disease dementia** |  |  |  |
| <65 years | 30 (7.0) | 5 (3.2) | 2.31 (0.88-6.08) |
| 65-74 years | 176 (41.3) | 29 (18.4) | 3.13 (2.00-4.89) |
| 75+ years | 220 (51.6) | 124 (78.4) | 0.29 (0.19-0.44) |
| **Unspecified** |  |  |  |
| <65 years | 169 (7.3) | 9 (2.7) | 2.84 (1.43-5.61) |
| 65-74 years | 516 (22.1) | 52 (15.3) | 1.55 (1.13-2.12) |
| 75+ years | 1,645 (70.6) | 275 (82.0) | 0.53 (0.39-0.71) |
| **Others** |  |  |  |
| <65 years | 124 (24.5) | 73 (20.1) | 1.28 (0.92-1.78) |
| 65-74 years | 174 (34.3) | 85 (23.4) | 1.70 (1.26-2.31) |
| 75+ years | 209 (41.2) | 205 (56.5) | 0.54 (0.41-0.70) |

**Supplementary Table 2.** Medication (ATC codification) at time of diagnosis in AD [n (%)].

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SveDem** †  (n=8,136) | **ReDeGi\***  (n=2,395) | **Odds ratio**  (95% CI) |
| **Anticholinesterase** (N06DA) | 6,000 (74.6%) | 1,512 (63.1%) | 1.71 (1.55-1.88) |
| **NMDA antagonists** (N06DX) | 883 (11.0%) | 498 (20.8%) | 0.47 (0.41-0.53) |
| **Antidepressants** (N06AB) | 1,700 (23.0%) | 571 (23.8%) | 0.95 (0.85-1.05) |
| **Antipsychotics** (N05A) | 312 (4.2%) | 219 (9.1%) | 0.43 (0.36-0.52) |
| **Anxiolytics and/or sleeping aids** (N05B + N05D) | 1,247 (16.9%) | 731 (30.5%) | 0.46 (0.41-0.51) |
| **Cardiovascular** (B01AA + B01AC + C02 + C03 + C07 + C08 + C09 + C10) | 4,392 (59.5%) | 1,839 (76.8%) | 0.44 (0.39-0.49) |

† SveDem missing values: antipsychotics 763; antidepressants 758; NMDA antagonist 127; anticholinesterase 91; anxiolytics and/or sleeping aids 773; cardiovascular 753; \*ReDeGi: 401 missing medication profile

**Supplementary Table 3.** Medication (ATC codification) at time of diagnosis in VaD [n (%)].

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SveDem** †  (n=4,207) | **ReDeGi\***  (n=245) | **Odds ratio**  (95% CI) |
| **Anticholinesterase** (N06DA) | 255 (6.1%) | 67 (27.3%) | 0.17 (0.12-0.23) |
| **NMDA antagonists** (N06DX) | 231 (5.6%) | 12 (4.9%) | 1.14 (0.63-2.07) |
| **Antidepressants** (N06AB) | 1,175 (27.9%) | 67 (27.3%) | 1.08 (0.80-1.44) |
| **Antipsychotics** (N05A) | 330 (8.1%) | 24 (9.8%) | 0.81 (0.52-1.25) |
| **Anxiolytics and/or sleeping aids** (N05B + N05D) | 1,009 (24.8%) | 76 (31.0%) | 0.77 (0.58-1.01) |
| **Cardiovascular** (B01AA + B01AC + C02 + C03 + C07 + C08 + C09 + C10) | 3,471 (85.2%) | 212 (86.5%) | 0.89 (0.61-1.30) |

† SveDem missing values: antipsychotics 146; antidepressants 145; NMDA antagonist 63; anticholinesterase 54; anxiolytics and/or sleeping aids 287; cardiovascular 131; \*ReDeGi: 74 missing medication profile

**Supplementary Table 4.** Medication (ATC codification) at time of diagnosis in mixed dementia [n (%)].

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SveDem** †  (n=5,568) | **ReDeGi\***  (n=592) | **Odds ratio**  (95% CI) |
| **Anticholinesterase** (N06DA) | 2,984 (54.2%) | 309 (52.2%) | 1.08 (0.92-1.28) |
| **NMDA antagonists** (N06DX) | 1,007 (18.3%) | 113 (19.1%) | 0.95 (0.76-1.18) |
| **Antidepressants** (N06AB) | 1,146 (21.7 %) | 135 (22.8%) | 0.93 (0.76-1.14) |
| **Antipsychotics** (N05A) | 285 (5.4%) | 68 (11.5%) | 0.43 (0.33-0.58) |
| **Anxiolytics and/or sleeping aids** (N05B + N05D) | 1,145 (21.7%) | 197 (33.3%) | 0.55 (0.46-0.66) |
| **Cardiovascular** (B01AA + B01AC + C02 + C03 + C07 + C08 + C09 + C10) | 4,065 (76.8%) | 504 (85.1%) | 0.57 (0.45-0.73) |

† SveDem missing values: antipsychotics 283; antidepressants 284; NMDA antagonist 77; anticholinesterase 59; anxiolytics and/or sleeping aids 287; cardiovascular 273; \*ReDeGi: 78 missing medication profile

**Supplementary Table 5.** Medication (ATC codification) at time of diagnosis in dementia with Lewy bodies [n (%)].

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SveDem** †  (n=695) | **ReDeGi\***  (n=199) | **Odds ratio**  (95% CI) |
| **Anticholinesterase** (N06DA) | 517 (74.9%) | 133 (66.8%) | 1.48 (1.05-2.08) |
| **NMDA antagonists** (N06DX) | 109 (15.8%) | 26 (13.2%) | 1.25 (0.79-1.98) |
| **Antidepressants** (N06AB) | 186 (27.9%) | 57 (28.6%) | 0.96 (0.67-1.37) |
| **Antipsychotics** (N05A) | 100 (15.0%) | 35 (17.6%) | 0.82 (0.54-1.26) |
| **Anxiolytics and/or sleeping aids** (N05B + N05D) | 143 (21.6%) | 55 (27.6%) | 0.72 (0.50-1.03) |
| **Cardiovascular** (B01AA + B01AC + C02 + C03 + C07 + C08 + C09 + C10) | 408 (61.4%) | 160 (80.4%) | 0.38 (0.26-0.56) |

† SveDem missing values: antipsychotics 29; antidepressants 29; NMDA antagonist 7; anticholinesterase 5; anxiolytics and/or sleeping aids 32; cardiovascular 30; \*ReDeGi: 44 missing medication profile

**Supplementary Table 6.** Medication (ATC codification) at time of diagnosis in Frontotemporal dementia [n (%)].

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SveDem** †  (n=515) | **ReDeGi\***  (n=115) | **Odds ratio**  (95% CI) |
| **Anticholinesterase** (N06DA) | 33 (7.0%) | 48 (41.7%) | 0.10 (0.06-0.17) |
| **NMDA antagonists** (N06DX) | 23 (4.9%) | 12 (10.9%) | 0.44 (0.21-0.91) |
| **Antidepressants** (N06AB) | 135 (30.5%) | 30 (26.1%) | 1.24 (0.78-1.97) |
| **Antipsychotics** (N05A) | 30 (6.8%) | 15 (13.0%) | 0.48 (0.25-0.93) |
| **Anxiolytics and/or sleeping aids** (N05B + N05D) | 85 (19.2%) | 29 (29.6%) | 0.70 (0.43-1.14) |
| **Cardiovascular** (B01AA + B01AC + C02 + C03 + C07 + C08 + C09 + C10) | 239 (53.7%) | 75 (76.5%) | 0.68 (0.40-0.94) |

† SveDem missing values: antipsychotics 74; antidepressants 72; NMDA antagonist 46; anticholinesterase 44; anxiolytics and/or sleeping aids 73; cardiovascular 70; \*ReDeGi: 32 missing medication profile

**Supplementary Table 7.** Medication (ATC codification) at time of diagnosis in Parkinson’s disease dementia [n (%)].

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SveDem** †  (n=426) | **ReDeGi\***  (n=129) | **Odds ratio**  (95% CI) |
| **Anticholinesterase** (N06DA) | 235 (55.4%) | 87 (67.4%) | 0.60 (0.39-0.90) |
| **NMDA antagonists** (N06DX) | 58 (13.7%) | 7 (5.6%) | 2.77 (1.23-6.24) |
| **Antidepressants** (N06AB) | 132 (31.7%) | 31 (24.0%) | 1.46 (0.93-2.30) |
| **Antipsychotics** (N05A) | 65 (15.6%) | 48 (37.2%) | 0.31 (0.19-0.48) |
| **Anxiolytics and/or sleeping aids** (N05B + N05D) | 84 (20.1%) | 35 (27.1%) | 0.67 (0.42-1.06) |
| **Cardiovascular** (B01AA + B01AC + C02 + C03 + C07 + C08 + C09 + C10) | 231 (55.4%) | 103 (79.8%) | 0.46 (0.28-0.75) |

† SveDem missing values: antipsychotics 9; antidepressants 9; NMDA antagonist 4; anticholinesterase 2; anxiolytics and/or sleeping aids 9; cardiovascular 70; \*ReDeGi: 29 missing medication profile

**Supplementary Table 8.** Medication (ATC codification) at time of diagnosis in unspecified dementia [n (%)].

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SveDem** †  (n=2,330) | **ReDeGi\***  (n=282) | **Odds ratio**  (95% CI) |
| **Anticholinesterase** (N06DA) | 509 (22.5%) | 116 (41.1%) | 0.41 (0.32-0.53) |
| **NMDA antagonists** (N06DX) | 198 (8.8%) | 72 (25.5%) | 0.27 (0.20-0.37) |
| **Antidepressants** (N06AB) | 627 (28.9%) | 62 (22.0%) | 1.44 (1.07-1.94) |
| **Antipsychotics** (N05A) | 217 (10.0%) | 28 (9.9%) | 1.01 (0.66-1.53) |
| **Anxiolytics and/or sleeping aids** (N05B + N05D) | 606 (28.0%) | 109 (38.7%) | 0.61 (0.47-0.79) |
| **Cardiovascular** (B01AA + B01AC + C02 + C03 + C07 + C08 + C09 + C10) | 1,370 (63.2%) | 233 (82.6%) | 0.36 (0.26-0.49) |


† SveDem missing values: antipsychotics 167; antidepressants 163; NMDA antagonist 68; anticholinesterase 68; anxiolytics and/or sleeping aids 168; cardiovascular 162; \*ReDeGi: 54 missing medication profile

**Supplementary Table 9.** Medication (ATC codification) at time of diagnosis in other dementia diagnoses [n (%)].

|  |  |  |  |
| --- | --- | --- | --- |
|  | **SveDem** †  (n=507) | **ReDeGi\***  (n=295) | **Odds ratio**  (95% CI) |
| **Anticholinesterase** (N06DA) | 92 (18.6%) | 68 (23.1%) | 0.76 (0.53-1.08) |
| **NMDA antagonists** (N06DX) | 25 (5.1%) | 11 (4.0%) | 1.37 (0.66-2.83) |
| **Antidepressants** (N06AB) | 140 (29.5%) | 72 (24.4%) | 1.29 (0.93-1.80) |
| **Antipsychotics** (N05A) | 59 (12.4%) | 48 (16.3%) | 0.72 (0.48-1.10) |
| **Anxiolytics and/or sleeping aids** (N05B + N05D) | 137 (28.8%) | 108 (34.6%) | 0.70 (0.51-0.95) |
| **Cardiovascular** (B01AA + B01AC + C02 + C03 + C07 + C08 + C09 + C10) | 261 (55.2%) | 229 (73.4%) | 0.35 (0.25-0.49) |

† SveDem missing values: antipsychotics 32; antidepressants 33; NMDA antagonist 12; anticholinesterase 13; anxiolytics and/or sleeping aids 32; cardiovascular 34; \*ReDeGi: 68 missing medication profile

**Supplementary Figure 1.** Coverage of SveDem in 2013 relative to the expected dementia incidence in the different regions of Sweden.

****

Reproduced with permission from SveDem from the SveDem yearly report from 2013 (Årsrapport 2013 available in Swedish at http://www.svedem.se). ©SveDem 2014